Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)
- Author:
Yusuke KOBAYASHI
1
;
Muneaki SHIMADA
;
Masato TAMATE
;
Hyun Woong CHO
;
Jun ZHU
;
Hung-Hsueh CHOU
;
Hiroaki KAJIYAMA
;
Aikou OKAMOTO
;
Daisuke AOKI
;
Sokbom KANG
;
Jeong-Won LEE
;
Jae-Weon KIM
;
Jae-Hoon KIM
;
Zhongqiu LIN
;
Jihong LIN
;
Xiaohua WU
;
Hung-Cheng LAI
;
Ting-Chang CHANG
;
Chyong-Huey LAI
;
Yong Man KIM
;
Takayuki ENOMOTO
Author Information
- Publication Type:Review Article
- From:Journal of Gynecologic Oncology 2024;35(3):e87-
- CountryRepublic of Korea
- Language:English
- Abstract: Ovarian cancer, notable for its severe prognosis among gynecologic cancers, has seen substantial progress in treatment approaches recently. Enhanced protocols in chemotherapy and the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors for maintenance therapy have markedly improved outcomes for patients with specific genetic profiles, such as those positive for BRCA mutations or exhibiting homologous recombination deficiency (HRD). Additionally, the method of intraperitoneal chemotherapy administration has emerged as a valuable alternative to traditional transvenous routes, showing promise for wider clinical adoption. The field of surgery has also evolved, with increasing exploration into the benefits and feasibility of laparoscopic methods over more invasive traditional surgeries, aiming for complete tumor removal but with reduced patient impact. The hereditary nature of ovarian cancer underscores the importance of genetic testing, which has become integral in tailoring treatment strategies, particularly in determining suitability for PARP inhibitors.The formation of the East Asian Gynecologic Oncology Trial Group (EAGOT) aims to optimize treatment across Japan, Korea, China, and Taiwan. The ovarian cancer committee of EAGOT shared the current policies, focusing on 5 topics: 1) strategies for maintenance therapy after initial surgery and chemotherapy, 2) drug regimens for platinum-sensitive and platinum-resistant recurrence, 3) intraperitoneal chemotherapy, 4) laparoscopic surgery as an alternative to laparotomy, and 5) current status of genetic testing (BRCA, HRD, and panel tests) for ovarian cancer and its prospects. EAGOT’s multi-national trials aim to harmonize these evolving treatment strategies, ensuring that the latest and most effective protocols are accessible across the region, thereby significantly impacting patient outcomes in East Asia.
